On April 24, 2026 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported its financial results for the first quarter of fiscal year 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Core revenue of ¥321.7 billion (+11.5%), core operating profit of ¥163.3 billion (+17.1%), and core net income of ¥118.6 billion (+19.6%) were achieved with strong sales performance of domestic and overseas products, resulting in increased revenue and profit (all changes year-on-year)
New product launches and additional indications included the launch of Elevidys as Japan’s first regenerative medical product for Duchenne muscular dystrophy (DMD), and the approval of Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large B‑cell lymphoma
R&D activities progressed steadily across both early and late-stage development, including Chugai-originated projects, with progress on track to achieving the highest number of application plans ever
NXT007 suggested favorable tolerability in Part C of the Phase I/II NXTAGE study for Hemophilia A following direct switching from Hemlibra without washout period
Enspryng presented Phase III results in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at the 2026 American Academy of Neurology Annual Meeting, and is preparing for regulatory application within the year
Regarding products out-licensed to third parties, FoundayoTM(orforglipron), an oral GLP‑1 receptor agonist out‑licensed to Eli Lilly, has obtained U.S. approval as a treatment for obesity and is currently under regulatory review in more than 40 countries, including Japan and the European Union
Refer to the information below for details on the financial results:

Quarterly Reports / Finance Reports
View Source

Presentation Materials
In addition to Chugai’s business and financial performance, these materials provide updates on our research and development pipeline. Videos and scripts (including Q&A) will be made available at a later date.
View Source

[2026 First Quarter Results]

Core results (Billion JPY)
2026 2025 % change
Revenue

321.7

288.5 +11.5%
Domestic sales 111.4 103.0 +8.2%
Overseas sales 180.1 156.7 +14.9%
Other revenue 30.2 28.7 +5.2%
Operating profit 163.3
139.5

+17.1%
Net income 118.6 99.2 +19.6%

(Press release, Chugai, APR 24, 2026, View Source [SID1234664753])